Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02750215 · ClinicalTrials.gov registry record · Phase 2
A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor
A Phase 2 study of Malignant Non-small Cell Neoplasm of Lung Stage IV, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02750215: Completed Phase 2 study of Malignant Non-small Cell Neoplasm of Lung Stage IV, sponsored by Massachusetts General Hospital.
NCT02750215 is a Phase 2 study of Malignant Non-small Cell Neoplasm of Lung Stage IV that has completed, run by Massachusetts General Hospital. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02750215, a Phase 2 study of Malignant Non-small Cell Neoplasm of Lung Stage IV, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying capmatinib as a treatment for advanced non-small cell lung cancer with MET exon 14 skipping, where the participant has already received prior therapy with a MET inhibitor.
Primary Outcome
Objective response rate (ORR) is defined as the percentage of patients with a complete response or partial response to treatment according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Complete response (CR) is the disappearance of all target lesions. Partial response (PR) is a greater than or equal to 30% decrease in the sum of the longest diameter of target lesions. ORR = CR + PR.
Conditions Studied
Interventions
- DRUG Capmatinib (INC280)
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-05 |
| Est. Completion | 2021-05 |
| Phase | Phase 2 |
What the finished NCT02750215 record still lists
NCT02750215 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Malignant Non-small Cell Neoplasm of Lung Stage IV appearing as the primary indexed condition, and to 1 intervention - of which Capmatinib (INC280) is the first listed.
NCT02750215 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02750215 about?
NCT02750215 is a clinical study titled "A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor". This research study is studying capmatinib as a treatment for advanced non-small cell lung cancer with MET exon 14 skipping, where the participant has already received prior therapy with a MET inhibitor.
What is the current status of trial NCT02750215?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2016-05. Estimated completion is 2021-05.
What conditions does trial NCT02750215 study?
This clinical trial studies the following conditions: Malignant Non-small Cell Neoplasm of Lung Stage IV.
What interventions are being tested in trial NCT02750215?
The interventions under investigation include: Capmatinib (INC280) (DRUG).
Who is sponsoring clinical trial NCT02750215?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02750215 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02750215's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia